Wuhan Fourth Hospital

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease3 trials
• Coronary artery disease1 trial
• High blood pressure1 trial
• Osteoarthritis1 trial
• Stroke1 trial
• Type 2 diabetes1 trial

Phase

• Phase 35 trials
• Phase 21 trial

Status

• Completed3 trials
• Active, not recruiting2 trials
• Recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• Boehringer Ingelheim2 trials
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology2 trials
• Guangdong Provincial People's Hospital1 trial
• Shenzhen Salubris Pharmaceuticals Co., Ltd.1 trial
• Tasly Biopharmaceuticals Co., Ltd.1 trial
• and 1 more

Running trials

• Recruiting

  A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)

  NCT07136792· Guangdong Provincial People's Hospital· Source

  Contact: Hua Li

• Recruiting

  The Application of an AI-driven Multimodal Predictive Model for Cognitive Impairment in Patients With Type 2 Diabetes Mellitus

  NCT07128186· Tongji Hospital· Source

  Contact: Mei Lin

• Recruiting

  Phase II Clinical Trial of UC-MSCs in the Treatment of Knee Osteoarthritis

  NCT07547735· Phase 2· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

  Contact: Qingsong Zhang

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  Efficacy and Safety of Colchicine After PCI

  NCT06472908· Phase 3· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease1 recruiting
• Osteoarthritis1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)

  NCT05700591· Phase 3· Tasly Biopharmaceuticals Co., Ltd.· Source

• Completed

  To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil

  NCT06500689· Phase 3· Shenzhen Salubris Pharmaceuticals Co., Ltd.· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source